ClinicalTrials.gg
Not yet recruitingNCT05999825Updated Oct 17, 2023

Sm-p80 Schistosomiasis Challenge Study

A Phase 2 interventional study of Sm-p80 + GLA-SE Vaccine and Placebo in Schistosoma Mansoni and Schistosomiasis, sponsored by Leiden University Medical Center. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Leiden University Medical Center · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn about the Sm-p80 + GLA-SE (Schistoshield®) vaccine in healthy participants who have not had schistosomiasis before. The main questions it aims to answer are:

  • if the vaccine is safe
  • if after vaccinated people start producing antibodies
  • if the vaccine works against schistosomiasis.

Participants will receive three vaccines (or placebo) and are then exposed to 20 male Schistosoma cercariae. Afterwards they are treated with praziquantel to cure the infection.

Researchers will compare the group vaccinated with Schistoshield® and placebo (fake vaccination) to see if the vaccine has worked.

02

Conditions studied

  • Schistosoma Mansoni
  • Schistosomiasis

Browse trials for

03

In context

Schistosomiasis

79 studies on the registry are indexed under Schistosomiasis; 14 are open to participants now.

This study's planned enrollment of 48 is below the median of 289 across 52 interventional studies indexed under Schistosomiasis.

Browse Schistosomiasis studies →

Lead sponsor

Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged ≥ 18 and ≤ 45 years and in good health.
  2. Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
  3. Subject is able to communicate well with the investigator, is available to attend all study visits.
  4. Subject will not travel to Schistosoma-endemic countries up until treatment at week 24.
  5. Subject agrees to refrain from blood and plasma donation to Sanquin or for other purposes throughout the study period.
  6. For female subjects: subject agrees to use adequate and not to breastfeed for the duration of study.
  7. Subject has signed .

Exclusion criteria

Exclusion Criteria:

  1. Any history, or evidence at screening, of symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, (severe) psychiatric and other disorders, which could compromise the health of the participant during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:

    • body weight \<50 kg or (BMI) \<18.0 or >35.0 kg/m2 at screening;
    • positive , or screening tests;
    • the use of immune modifying drugs within three months prior to study onset (inhaled and topical and oral anti-histamines exempted) or expected use of such during the study period;
    • history of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years;
    • any history of treatment for severe psychiatric disease by a psychiatrist in the past year;
    • history of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
  2. The chronic use of any drug known to interact with praziquantel, artesunate or lumefantrine metabolism (e.g. phenytoïn, carbamazepine, phenobarbital, primidon, dexamethason, rifampicine, cimetidine, flecaïnide, metoprolol, imipramine, amitriptyline, clomipramine, class IA and III anti-arrythmics, antipsychotics, antidepressants, macrolides, fluorchinolones, imidazole- and triazole antimycotics, antihistamines). Because lumefantrine may cause extension of -time, chronic use of drugs with effect on QT interval will result in exclusion from study participation.
  3. Any planned vaccination within 28 days before the start of the trial until the end of the immunisation phase (week 12), with the exception of SARS-CoV-2 vaccines or influenza vaccines.
  4. For female subjects: positive serum pregnancy test on the day before first immunisation.
  5. Any history of schistosomiasis or treatment for schistosomiasis.
  6. Positive serology for schistosomiasis or elevated serum CAA at screening.
  7. Known to or (including co-medication) for use of praziquantel, artesunate or lumefantrine.
  8. Being an employee or student of the department of Parasitology or Infectious diseases of the LUMC.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Vaccine group

    The vaccine group will be immunised three times with 30 μg Sm-p80 + 5 μg GLA-SE i.m. at weeks 0,4, and 8. Participants will be exposed to 20 male Schistosoma mansoni cercariae at week 12.

    Biological: Sm-p80 + GLA-SE Vaccine · Biological: Schistosoma mansoni infection

  • Placebo comparator
    Placebo control group

    The placebo control group will be immunised three times with saline i.m. at weeks 0,4, and 8. Participants will be exposed to 20 male Schistosoma mansoni cercariae at week 12.

    Other: Placebo · Biological: Schistosoma mansoni infection

Interventions

  • BiologicalSm-p80 + GLA-SE Vaccine

    30 μg Sm-p80 + 5 μg GLA-SE

  • OtherPlacebo

    0.9% Sterile Normal Saline

  • BiologicalSchistosoma mansoni infection

    20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain

06

What researchers measure

Primary outcomes

  1. Vaccine efficacy

    The protective efficacy of Sm-p80 + GLA-SE to male Sm cercariae measured by the difference in frequency of serum CAA positivity (≥1.0 pg/mL) between the vaccine group and placebo

    Time frame: week 12-24, i.e. after challenge

Secondary outcomes

  1. Safety of (repeated) immunisation

    Frequency and severity of adverse events after (repeated) immunisation with Sm-p80 + GLA-SE

    Time frame: week 0-12

  2. Immunogenicity

    Anti-Sm-p80 IgG antibody titres after (repeated) immunisation with Sm-p80 + GLA-SE measured by ELISA

    Time frame: week 0-24

Other outcomes

  1. Time to CAA positivity

    Comparison of time to positive serum CAA test between the vaccine and placebo groups after exposure to male Sm cercariae at week 12

    Time frame: week 12-24

  2. Peak CAA levels

    Comparison of peak serum CAA concentrations between the vaccine and placebo groups after exposure to male Sm cercariae at week 12

    Time frame: week 12-24

  3. Eosinophils

    Comparison of peak eosinophil counts between the vaccine and placebo groups after exposure to male Sm cercariae at week 12

    Time frame: week 12-24

  4. Antibody responses

    Comparison of (glycan) antibody responses directed against Sm antigens between the vaccine and placebo participants as well as between protected and non-protected participants after exposure to male Sm cercariae at week 12 using protein and glycan arrays

    Time frame: week 0-24

  5. Cellular responses

    Comparison of cellular responses directed against Sm antigens between the vaccine and placebo groups after immunisation and after controlled human infection with Sm cercariae, as well as between protected and non-protected participants

    Time frame: week 0-24

  6. In vitro killing

    Enumeration of the ability of Sm-p80-specific antibodies from human subjects to kill schistosome larvae in vitro from sera collected prior to each vaccination

    Time frame: week 0-24

  7. Transcriptomic profile

    Identification, characterization and comparison of gene expression changes as measured using RNA-seq analysis from PBMC between placebo and vaccine groups

    Time frame: week 0-24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05999825
Collaborators
Texas Tech University Health Sciences Center, MRC/UVRI and LSHTM Uganda Research Unit
Responsible party
Meta Roestenberg (Prof., Leiden University Medical Center) — Principal investigator
First posted
Aug 21, 2023
Start date
Sep 2024 (estimated)
Primary completion
Apr 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Oct 17, 2023

Study contacts

Meta Roestenberg, Prof
Contact
M.Roestenberg@lumc.nl
+31715269111
Meta Roestenberg, Prof
principal investigator · LUMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion